TransCode Therapeutics, Inc. (RNAZ)
| Market Cap | 16.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.83M |
| Shares Out | 12.98M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,311 |
| Open | 1.35 |
| Previous Close | 1.29 |
| Day's Range | 1.28 - 1.40 |
| 52-Week Range | 1.13 - 5.28 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.20 (+690.7%) |
| Earnings Date | Aug 22, 2022 |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA"based a... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 690.70% from the latest price.
News
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported finan...
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its int...
TransCode Therapeutics to Participate at BIO International Convention
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 i...
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue f...
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution ...
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for ...
TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20 Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20
TransCode Therapeutics Reports 2021 Results; Provides Business Update
Company to host investor update call Thursday, April 7, at 4:30 p.m. ET Company to host investor update call Thursday, April 7, at 4:30 p.m. ET
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an intervie...
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based...
BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, M...
CORRECTION --TransCode Therapeutics
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (...
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode's C...
TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode's ...
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of R...
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit
Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. Trans...
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and ef...
RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today
TransCode Therapeutics (RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study. The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransC...
Here's why TransCode Therapeutics stock is up about 65% on Thursday
Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-...
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?
TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. Related: TransCode Therapeutic...
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Pote...
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective deli...
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective del...
TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development
TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeuti...